Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.52 per share for the second quarter of 2025, surpassing the ...

Vertex Pharmaceuticals Incorporated today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular ...

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

"ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic ...

Alyftrek was licensed in the UK in March this year and approved for use by the European Medicines Agency (EMA) in April. Alyftrek was previously designated as an orphan medicine by the EMA.

The approval of ALYFTREK, our fifth CFTR modulator regimen, represents another significant milestone in that journey for people with CF in the UK," said Carmen Bozic, M.D., Executive Vice ...

ALYFTREK is currently licensed in the U.S., the UK and the European Union and is under regulatory review in Canada, Switzerland, Australia and New Zealand. About Vertex ...

Vertex also presented the results of a post hoc analysis from the Phase 3 randomized, controlled and open-label trials of ALYFTREK (abstract WS19.04) which suggest treatment with ALYFTREK is ...

Vertex Pharmaceuticals announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK ®, a once-daily next-in-class triple ...

ALYFTREK or TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B). ALYFTREK should only be considered when there is a clear medical need and benefit ...